Mizuho Maintains Neutral on Amylyx Pharma, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Neutral rating on Amylyx Pharma (NASDAQ:AMLX) and lowers the price target from $4 to $3.
May 14, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a Neutral rating on Amylyx Pharma and lowers the price target from $4 to $3.
The reduction in price target by Mizuho reflects a negative outlook on the stock's short-term price potential, likely leading to a decrease in investor confidence and a potential drop in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100